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1. Introduction
Cells dedicate a considerable amount of energy and regulatory mechanisms to ensure cell-cell
communication, for this biological process is an important aspect of their machinery of
survival, behavior and fate within their immediate environment. For cells, communicating is
vital not only because they are part of organs and tissues of which they contribute to main‐
taining the integrity and proper function [1-5], but also because many of their functions need
to be coordinated, quantitatively fine-tuned and/or limited in space and time. Furthermore,
cells make use of communication to minimize the energetic and signaling burden, whereas a
single minimal signal could be amplified and propagated, as is for instance the case of gap
junction-mediated transfer of pro-apoptotic signals [6-8]. Many types of intercellular commu‐
nication have been studied, among which direct cell-cell interactions could be distinguished
from cellular interactions via released growth factors and cytokines. Their studies have
revealed a significant potential for use in cancer therapy. The importance of cell-cell commu‐
nication is particularly well revealed when defects in this process result in serious diseases, as
exemplified by mutations identified in many gap and tight junction proteins [9, 10].
The diversity of the types of intercellular communications (i.e. gap junctions (GJ), tight
junctions (TJ), adherens junctions (AJ) and desmosomes), implicates a diversity of signaling
pathways and biological functions at stake. It further emphasizes the need for cells to com‐
municate in different ways and for different purposes: transfer of small molecules, reciprocal
signaling, establishment of barriers and polarity, control of paracellular permeability and
transmission of cytoskeleton-generated forces. All of these processes have been implicated in
cancer development as reviewed previously for GJs [11-13], TJs [14, 15] and desmosomes [16].
In this chapter we will present an overview of how various types of direct cell-cell communi‐
cation and different groups of intercellular-dependent protein interactions have been used in
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strategies of gene therapy of cancer. Important concepts and paradigms as well as successful
approaches, limitations and possibilities for the future will be discussed.
2. Intercellular communication & gene therapy: The enzyme/prodrug
strategy
Cancer gene therapy has since its beginnings faced a major hurdle, the inefficiency of the
methods of gene delivery to target cells (i.e. transfection and infection). While attempts have
later been made to identify promising alternatives, a key development was the discovery that
gap junctions could provide an efficient method that, without directly reaching every cell,
could transfer the cytotoxic signal originating from a limited number of target cells to their
bystander neighboring cells, thus amplifying the therapeutic effect. This process has subse‐
quently been called “bystander effect” (BE) [17]. Triggering apoptotic death process in target
cells results in the transfer of the pro-apoptotic signaling molecules to other cells with which
they interact via gap junction intercellular communications (GJICs), and ultimately in the
demise of both cells. The BE thus plays an important role in the efficiency of cancer therapy
[18]. It also impacts the therapeutic cytotoxic side effects: since high doses of drugs are not
required to kill tumor cells, normal tissues may not be reached by the treatment.
3. Use of the bystander effect in the enzyme/prodrug cancer gene therapy
Gene therapy soon became the major therapeutic application of the BE in the so-called “suicide
gene therapy” involving the use of Enzyme/Prodrug cytotoxic systems, whereby target cells
express an enzyme that converts a prodrug into the cytotoxic active drug, which is then
transferred via gap junctions to the interacting cells [19]. The general mechanism is that the
active molecules are therefore transmitted to neighboring cells via GJIC and trigger their death
[20]. GJIC and connexins are essential for the BE-based enzyme/prodrug therapy [21-26]
(Figure 1). Different enzymes/prodrugs have been assayed among which cytosine deaminase
(CD)/5-fluorocytosine (5-FC), carboxylesterase/Camptothecin, and Herpes Simplex Virus-
thymidine kinase (HSV/tk)/Ganciclovir (GCV) are prominent [27]. The CD/5-FC combination
is based on the conversion of the nontoxic prodrug 5-FC by bacterial or yeast enzyme cytosine
deaminase into active 5-fluorouracil (5-FU) [28]. Similarly, GCV, a nontoxic purine analogue,
is phosphorylated by the enzyme HSVtk and by endogenous kinases to GCV-triphosphate,
which kills cells by inhibiting DNA synthesis [29] [30]. The carboxylesterase activates the
prodrug irinotecan,7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin
(CPT-11) to the active metabolite SN-38. Another combination including the uracil phosphor‐
ibosyltransferase (UPRT) of E. coli and 5-fluorouracil (5-FU), has also been used in BE-based
gene therapy, along with other less known systems. UPRT is an enzyme that catalyzes the
synthesis of UMP from uracil and 5-phosphoribosyl-alpha-1-diphosphate [31].
The therapeutic potential of the HSVtk and nucleosides’ combination has been assayed as
early as the 70’s and later extended to many types of cancers both in vitro and in vivo [32-41].
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Originally tried using retroviral vectors, the same approach adapted to adenoviral vectors
was later introduced and used successfully [42-44]. These and subsequent studies, all have
in common the use of an efficient delivery system, mostly adenoviral, modified to improve
the transduction efficiency or selectivity, in combination with an enzyme/prodrug system,
most often the HSVtk/GCV, to achieve cancer cells’ cytotoxicity. Virus-free delivery has also
been attempted using liposomes for instance, with more or less good efficacy [45-47], but
most of the studies have used viral delivery.
Figure 1. The enzyme/prodrug system and the bystander effect. Delivery via viral or non viral vectors of DNA se‐
quences expressing an enzyme, here the herpes simplex virus thymidine kinase gene (TK) in the presence of the pro‐
drug inactive substrate, here ganciclovir (GCV), results in the synthesis of the active metabolite, here GCV triphosphate
(GCV-tp), which kills not only the target cell, but the neighboring bystander cell as well. This 'bystander effect‘ is medi‐
ated by a direct transfer of cytotoxic signals through gap junctions (GJ)-mediated intercellular communication.
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3.1. Combination of oncolytic viruses and enzyme-prodrug gene therapy
Viruses are preferred vehicles for the transfer and delivery of engineered genes into host
cells in gene therapy approaches. Recently, they have emerged as not only delivery vec‐
tors,  but  as  bona  fide  therapeutic  agents  [74-77]  (Figure  2).  Oncolytic  replication-compe‐
tent  viruses  infect,  replicate  in  and  kill  tumor  cells.  Examples  abound  of  attempts  to
combine gene therapy and oncolytic virotherapy. Furthermore,  the enzyme/prodrug sys‐
tems have been used to improve the anti-tumor efficacy of oncolytic viruses. Early stud‐
ies  addressing  the  use  of  HSV vectors  as  oncolytic  agents,  showed that  HSV-mediated
oncolysis is enhanced by ganciclovir treatment through bystander effect [78]. A recombi‐
nant  HSV (M012)  was  constructed to  express  the  bacterial  CD gene and was shown to
enhance  the  prodrug-mediated  anti-tumor  effects  after  intracranial  delivery  in  murine
neuroblastoma and human glioma cells  [79].  An oncolytic  adenovirus  modified  to  bear
the human telomerase promoter (hTERT), was used to deliver the gene for the prodrug-
activating  enzyme  carboxypeptidase  G2  (CPG2)  to  tumors.  The  CPG2  metabolizes  the
prodrug ZD2767P into  a  cytotoxic  drug and this  strategy was  shown to  be  effective  in
colorectal  carcinomas  via  bystander  effects  and induction  of  apoptosis  [80].  A  recombi‐
nant Vesicular stomatitis virus (rVSV) encoding the CD/UPRT fusion gene was delivered
intratumorally in the presence of the systemically administered 5-FU and significantly re‐
duced  growth  of  lymphoma  and  breast  cancer  cells  in  vivo.  This  effect  involved  three
mechanisms:  a  strong bystander effect,  the viral  oncolytic  activity as  well  as  the activa‐
tion of  the immune system against  the tumor [81].  Recombinant  vesicular  stomatitis  vi‐
rus (VSV) made to express CD/UPRT was delivered to breast cancer cells in combination
with 5-fluorocytosine (5FC) [82]. An oncolytic adenovirus Ad5/3-Delta24FCU1 expressing
the fusion suicide gene FCU1, which encodes a bifunctional fusion protein that metabo‐
lizes  5-FC,  was  found  to  exert  significant  anti-tumor  activity  in  vitro  and  in  vivo  in  a
murine  model  of  head  and  neck  squamous  cell  carcinoma  [83].  ONYX-015  (dl1520),  a
conditionally  replicating  adenovirus  (CRAd)  made of  an  E1B-55k-deleted oncolytic  ade‐
novirus and which has anti-tumor effects [84], has been combined with the CD/5-FC sys‐
tem  and  the  enzyme/prodrug  system  involving  E.  coli  nitroreductase  (NTR)  which  can
reduce nitro(hetero)aromatic  compounds to hydroxylamines and amines,  and both com‐
binations  showed enhanced efficacy in  vitro  and in  vivo  [85,  86].  Similarly,  an  oncolytic
measles  virus  (MV)  armed with  the  prodrug  convertase,  purine  nucleoside  phosphory‐
lase  (PNP)  and the  prodrug 6-methylpurine-2'-deoxyriboside  (MeP-dR),  was  tested  in  a
model  of  murine  colon adenocarcinoma cells  in  syngeneic  C57BL/6  mice  and shown to
have anti-tumorigenic effects after systemic delivery [87]. In spite of this available litera‐
ture, many questions remain open. The factors defining the efficacy of this combinatorial
therapy are not clearly identified and the strategy might not have any advantage in cer‐
tain contexts. For instance, an oncolytic adenovirus, selective for the Rb/p16 pathway, kil‐
led  ovarian  cancer  cells  effectively  by  Tk/GCV-driven  BE.  However,  while  GCV
improved the adenoviruses’  antitumor efficacy over the replication-deficient  virus coun‐
terpart,  it  did not further enhance its  efficacy in vivo,  suggesting that the prodrug strat‐
egy may not add antitumor activity to highly potent oncolysis [88].
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3.2. Combined use of the enzyme/prodrug cancer gene therapy and gap junction
communication restoration
Although since the beginning of the use of the enzyme/prodrug approach, it was found that
the BE involves effects that do not depend on direct cell-cell interaction and are rather related
to diffusible molecules released extracellularly and possibly to immune-related effects [48-51],
the role of gap junctions-mediated intercellular communication (GJIC) and connexins was
deemed essential [25, 26, 52-54] [55]. In light of the observed loss of connexins’ expression in
many cancers, the efficiency of the enzyme/prodrug approach could be limited by the ability
of tumor cells to undergo GJICs between gene-transduced and bystander non-transduced cells.
The levels of connexins and GJIC could modulate the impact of the bystander effect of the
prodrug/enzyme systems, as shown for HSVtk/GCV in vitro and in vivo [56, 57]. This was
suggested to be a reason behind the limited efficacy of the viral HSVtk/GCV delivery in many
reports [58-60]. Nevertheless, many attempts have been made to bypass this limitation by
restoring connexins’ expression and the ability to undergo GJIC. This could be achieved either
by the direct delivery of Cx-encoding vectors [61-64] or by pharmacological induction of Cx
expression. The later approach involved for instance treating with DNA demethylating agents
[65], histone deacetylases’ inhibitors (HDACi) [66-68], ATP-sensitive potassium (KATP)
channels’ inhibitors [69], treatment with all-trans retinoic acid [70] or cyclic-AMP [71-73].
3.3. Applications of the enzyme/prodrug gene targeting of stem cells
Cellular vectors, including stem cells, have been used for effective gene delivery in cancer
therapy. Stem and progenitor cells have been acknowledged as important for both normal and
cancer homeostasis. In particular, according to the cancer stem cells’ theory, tumors contain a
very small sub-population of self-renewing and highly proliferating cells called cancer stem
cells (CSCs), which are responsible for the tumorigenic activity [89]. Mesenchymal stem cells
(MSCs), which have a strong tropism for tumor cells, are another type of stem cells of impor‐
tance in cancer understanding and therapeutic targeting [90]. The use of allogeneic and hence
escaping immune vigilance mesenchymal stromal cells (MSCs), sometimes called mesenchy‐
mal stem cells, as Trojan horses to deliver the enzyme/prodrug within the tumor mass is a
relatively new development in gene therapy. MSCs are used as carriers of the enzyme via viral
transduction, which subsequently activates the prodrug and kills not only the MSCs but their
neighboring cancer cells (Figure 2). This strategy has been tested in many cancers, as illustrated
by the following examples.
It has been shown that MSCs localize primarily to the perivascular environment in many
organs and, when implanted or injected into animals, they show a tropism for primary tumors
and metastases, and specifically for the perivascular niches within tumors [91, 92]. Based on
this preferential migration, MSCs have been used as a vehicle in gene therapy strategies [93,
94]. The cytosine deaminase prodrug system has been partnered with the human MSCs and
the combination increased the bystander effect and selective cytotoxicity on target tumor cells
in vitro and in vivo [95-97]. Similarly, human neural stem cells (NSCs) have been successfully
used to therapeutically target brain cancers. In fact, both MSCs and NSCs show high tropism
for brain cancers and have been combined with the prodrug system to target brainstem
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gliomas, a form of childhood central nervous system tumors with poor prognosis or medul‐
loblastomas [98-101], and even in disseminated brain metastases of non-neuronal origins such
as melanoma and breast cancer [102-104]. The success of this approach now warrants clinical
trials such as the one recently started to study the feasibility of intracerebral administration of
NSCs in combination with oral 5-FC in patients with recurrent high-grade gliomas [105].
Figure 2. Different approaches of intercellular communication-based gene therapy. Tumor cells (TC) are targeted
with oncolytic viruses which, in addition to their proper cytotoxic effects [1], could be combined with the bystander
effect ensured by the enzyme/prodrug system, here for example the TK/GCV pair [3]. TCs are made sensitive to the
bystander effect cytotoxic effects by inducing connexin (Cx) expression and the formation of gap junction intercellular
communication. This is achieved by either 4) viral vectors, or 5) pharmacological inducers. Cellular delivery of the viral
vectors for the enzyme/prodrug system could also be achieved using mesenchymal stem cells (MSCs) and other types
of stem/progenitor cells [6].
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Based on the tropism shown by neural stem cells (NSCs) for glioma cells, the herpes simplex
virus-thymidine kinase (HSVtk)/GCV system has also been used in targeting gliomas
[106-108]. However, for practical reasons related to the availability of cells, the use of MSCs
might be more relevant clinically than the use of NSCs [109]. The system has also been test‐
ed for AT-MSCs [110] and bone marrow-derived tumor-infiltrating cells (BM-TICs) target‐
ing of gliomas [111]. It was also proven to have a strong anti-tumor growth in
medulloblastomas [112].
As discussed earlier, a major limitation to the efficacy of the therapeutic use of GJIC is the
deficiency in the bystander effect due to low expression levels of connexins. Expectedly, this
is also a challenge when using the prodrug/stem cells combined therapy. This can be bypassed
by restoring connexin levels. For instance, GSCs showed more reduced GJIC and connexin
levels than differentiated glioma cells [113]. Valproic acid (VPA) was able to upregulate Cx43
and Cx26 and to enhance the bystander effect of suicide gene therapy by human bone marrow
MSCs expressing HSV-TK (MSCs-TK) [114]. In another study, the use of Bone marrow-derived
stem cells (BMSCs) in combination with the (HSV-TK)/GCV suicide gene therapy of gliomas
was improved by Cx43 overexpression in vitro and in vivo [115].
The MSC/Prodrug and Oncovirus/Prodrug strategies are often combined. For instance, MSCs
transduced with an adenoviral vector modified to express integrin-binding motifs
(Ad5lucRGD) for better transduction efficiency, and expressing thymidine kinase were able
not only to kill ovarian cancer cells via bystander effect, but also support replication of
adenoviruses which could result in further sustaining the effect [116].
MSCs can also act through an anti-angiogenic mechanism. They have been shown to target
endothelial cells and inhibit capillary growth, establish Cx43-based GJIC with the target ECs,
and to increase the production of reactive oxygen species (ROS). This effect culminates in the
induction of apoptosis, thus inhibiting tumor growth in a model of melanomas [117].
3.4. The enzyme/prodrug approach in non-gap junctional communications
Curiously, unlike gap junctions, the number of studies delivering tight and adherens junctions
or desmosomal proteins for cytotoxic gene therapy is limited. The adenoviral delivery of TK
and E-cadherin genes improved TK/GCV cytotoxicity and antitumoral activity in pancreatic
cancer cells [118].
Nevertheless, other cell-cell adhesion proteins, either or not with known links to these
junctions, have been targeted in the enzyme/prodrug approach, as illustrated by the following
examples. Carcinoembryonic antigen (CEA), a glycoprotein involved in cell-cell adhesion as
well as cell-extracellular substrate adhesion, is a particularly prolific case. The expression of
CEA in cancer cells with the exclusion of adult normal cells has been used in multiple ways to
provide specificity to the Enzyme/Prodrug system. This directed enzyme/prodrug therapy,
involves the generation of a recombinant plasmid, containing CEA promoter to specifically
drive the expression of the enzyme/prodrug systems in CEA-expressing cancer cells [119-121].
The E. coli purine nucleoside phosphorylase (ePNP) under the control of CEA promoter
sequences greatly improved the antitumor efficacy of the ePNP/MePdR killing system in
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pancreatic cancer cells [122]. The use of the double system including TK/GCV and CD/5-FC,
in CEA-positive lung cancer cells, resulted in enhanced cytotoxicity [123]. A CEA promoter-
regulated oncolytic adenovirus vector driving the Hsp70 gene expression in CEA-positive
pancreatic cancer cells was also active in vitro and in vivo [124]. Similar results were obtained
by targeting suicide gene CD expression to colon cancer cells [125]. An E1A, E1B double-
restricted oncolytic adenovirus, AxdAdB-3, improved the therapeutic efficacy of the
HSVtk/GCV system in gallbladder cancers when directed by the CEA promoter [126]. A
modification of the approach done earlier, involved the addition of four tandem-linked NF-
kappaB DNA-binding sites (kappaB4) and a kappaB4 enhancer upstream of the CEA promoter,
thus sensitizing colon cancer cells to the thymidine phosphorylase (TP)/ 5-fluorouracil (5-FU)
or 5'-deoxy-5-fluorouradine (5'-DFUR) combinations [127]. A different way of targeted
delivery of adenoviral vectors involved the generation of a bispecific adapter protein (sCAR-
MFE), consisting of a fusion of the ectodomain of the coxsackie/adenovirus receptor (sCAR)
with a single-chain anti-CEA antibody (MFE-23) [128]. A specific CEA RNA-targeting
ribozyme was developed and used for selective delivery of HSVtk/GCV cytotoxic activity, into
CEA-expressing cancer cells [129].
A high affinity antibody for Neural cell  adhesion molecule 2 (NCAM2), a cell-cell  adhe‐
sion molecule,  which is  also capable of  cell-extracellular  matrix  adhesion,  was useful  in
increasing  transduction  efficiency  of  a  fiber-modified  adenoviral  vector  Adv-FZ33  in
prostate and breast cancers,  and restoring sensitivity to the UPRT/5-FU system in previ‐
ously  resistant  cells  [130].  An Adenoviral  vector  incorporating  an  IgG Fc-binding  motif
(Z33)  from the  Staphylococcus  protein  A (Ad-FZ33)  combined with  tumor-specific  anti-
EpCAM  (epithelial  cell  adhesion  molecule)  antibodies  improved  the  viral  transduction
and the growth suppression of biliary cancer xenografts in nude mice in response to the
UPRT/FU combination in  human biliary cancers  [131].  A similar  approach used the en‐
zyme/prodrug  system comprised  of  the  enzyme carboxylesterase  (CE)  and its  substrate
the  anticancer  agent  CPT-11  (irinotecan  or  7-ethyl-10[4-(1-piperidino)-1-piperidino]  car‐
bonyloxycamptothecin).  An adenoviral  vector Ad.C28-sCE2 containing a fusion gene en‐
coding  a  secreted  form of  human liver  CE2  targeted  to  EpCAM was  efficient  in  colon
cancer spheroids [132]. As for CEA, the validation of the use of the EpCAM promoter to
target the HSVtk/GCV therapy to cancer cells has been performed [133].
4. Gene therapy using bystander effect-independent intercellular
communications
The prominence of BE-based gene therapy in the literature should not eclipse the importance
of other intercellular communications which do not involve the BE as candidates for gene
therapy. These include in addition to a GJIC-independent role of connexins, other types of cell-
cell junctions as well as other types of protein-protein (ligand-receptor) interactions who
depend on cell-cell interactions for their functions. Although to different extents, all these
intercellular events have proven very amenable to gene therapy strategies.
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4.1. GJIC-independent effects
The key players in the BE are connexins, the building blocks of gap junctional intercellular
communication (GJIC) [23, 134, 135]. Even though the effectiveness of restoring Connexins’
and GJIC’s levels has traditionally been associated with the bystander effect in gene therapy,
it has become clear that many functions of connexins, could be dissociated from both GJIC and
the bystander effects [136-138] [139] [140] [141]. In this case, delivery of Cxs-encoding vectors
could be used as a gene therapy approach, regardless of the use of enzyme/prodrug systems.
However, future use of such application requires a better understanding of the non GJIC-
related functions of these proteins, including their interacting partners and the mechanisms
of their subcellular localization.
4.2. Desmosomes, adherens and tight junctions in gene therapy
Adherens junctions and their related desmosomes, as well as tight junctions are essential types
of cell-cell adhesion in both normal homeostasis and tumor progression [142-148]. Claudins
are key tight junction proteins whose expression is deregulated in many cancers [146, 149].
Claudins CLDN3 and CLDN4 function as receptors for the Clostridium perfringens entero‐
toxin (CPE) produced by the bacterial Clostridium type A strain, resulting in cell death. A gene
therapy application based on CPE gene transfer-mediated cytoxicity has been achieved but,
as expected, was limited to CLDN3- and CLDN4-overexpressing tumors [150]. SiRNA-
mediated silencing of the expression of Epithelial Cell Adhesion Molecule (EpCAM or CD326),
a cell-surface protein involved in tight junctions and metastasis in colon, breast and other
epithelial carcinomas, was effective in decreasing the growth of breast cancer cells [151]. The
same approach was used with an antibody against the carcinoembryonic antigen (CEA) in
gastric cancer [152]. In fact, CEA has been extensively targeted in gene therapy approaches in
different ways. A recombinant form of the oncolytic measles virus Edmonston strain (MV-
Edm) changed to express CEA, demonstrated high cytotoxicity towards hepatocellular
carcinoma cells in vitro and in vivo after either Intratumoral or intravenous delivery [153]. The
cell adhesion molecule CECAM1, or carcinoembryonic antigen-related cell adhesion molecule
1, has served in an adenoviral gene therapy targeting prostate cancer cells and showed tumor
suppressor activities in vivo [154].
It is noteworthy that even when targeting these cell-cell communications could not be di‐
rectly performed or if it fails to affect tumor growth, there is no doubt about their impact
on gene therapy applications.  Cell-cell  communications could indeed constitute a source
of impediment to gene therapy, by constituting physical barriers to tumor targeting with
oncolytic viruses in vivo  [155] [156, 157]. This is particularly important in tissues such as
the lung, intestine and reproductive system which show natural mechanisms of resistance
to viral  infection and might thus be less amenable to viral  gene delivery.  In fact,  many
junction proteins have been shown to be receptors for many viruses. The protein original‐
ly known as coxsackie-adenovirus receptor (hCAR), which was used in adenoviral-based
gene therapy for cancer before realizing that it is a component of epithelial tight junctions
[158, 159], affects the efficacy of the adenoviral gene therapy approach [160, 161]. Desmo‐
glein-2 (DSG-2), a desmosomal adhesion glycoprotein, is a receptor used by adenoviruses
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Ad3, Ad7, Ad11 and Ad14, which subsequently results in epithelial-to-mesenchymal tran‐
sition-like  changes  and transient  opening of  intercellular  junctions,  a  finding that  could
have an impact on the adenoviral gene delivery to normal or cancer cells [162, 163]. Adhe‐
rens  junction  proteins  Nectin-1  and -2  are  entry  receptors  for  the  herpes  simplex  virus
types  1  (HSV-1)  and 2  (HSV-2)  [164-166].  Increasing Nectin-1  expression resulted in  in‐
creased susceptibility to HSV-1 infection and oncolytic activity and hence enhanced tumor
regression in vivo [167]. Attenuated HSV-2 viral production in WB rat liver epithelial cells
was found to depend on the viral protein co-localization with adherens junction proteins
rather than by the status of gap junctions [168]. Taken together, these studies demonstrate
the importance of  junctional  proteins  in  the  infectivity  of  viruses  and suggest  that  they
might impact the efficacy of the viral oncolytic gene therapies. Compounds could thus be
identified for example to improve viral gene transfer [169].
4.3. Intercellular communications-dependent protein-protein interactions
Many proteins, although not bona fide  components of cell-cell  junctions, are either affect‐
ed by these interactions or  are  very important  in  the function of  direct  cell-cell  interac‐
tions,  whether  junctional  or  not.  Prototypes  of  these  proteins  are  the  ones  involved  in
axon guidance, such as the Eph/Ephrin proteins. The Eph family is the largest family of
receptor  tyrosine  kinases,  and  includes  the  A-type  Eph  (EphA1–10)  and  B-type  Eph
(EphB1–6)  receptors  as  well  as  A-type  Ephrin  (EphrinA1-6)  and  B-type  Ephrin  (Eph‐
rinB1-3) ligands. A particularity of this family is that,  with few exceptions, the receptor-
ligand  interactions  depend  on  direct  cell-cell  contacts,  as  both  Ephs  and  Ephrins  are
anchored  in  interacting  cellular  membranes  and  in  fact  their  role  in  cell-cell  repulsion/
attraction and cell  sorting  is  one  of  their  main  features.  Study of  Ephs/Ephrins’  role  in
cancer has dramatically boomed in the last  decade [170] and attempts are currently un‐
derway to target them in cancer therapy. Targeting of Ephs and Ephrins for gene thera‐
py has been very timid so far. EphA2 is probably one of the most sought after receptors
of this family, as its expression is increased in many cancers and it has shown pro-onco‐
genic  functions.  A human adenoviral  type  5  (HAd)  vector  expressing  a  secreted fusion
protein constituted of  the extracellular  domain of  EphrinA1,  an EphA2 ligand,  fused to
the  Fc  portion of  IgG1,  was  used to  infect  mammary epithelial  cells  and was  found to
activate and induce the degradation of EphA2, thus showing anti-tumor effects. After in‐
tratumoral inoculation, the HAd-EphrinA1-Fc vector significantly inhibited tumor growth
in vivo  [171,  172].  On the other hand,  taking advantage of  the high expression levels  of
EphA2 in cancer cells, an EphA2-binding peptide has been added to an Adenoviral vec‐
tor (Ad) to target pancreatic  cancer cells  and bypass the limitation of low Ad transduc‐
tion due to low levels of the major Ad receptor called Coxsackie and Ad receptor (CAR)
[173]. Recently, EphA2 has been shown to be an essential receptor for the Kaposi's sarco‐
ma–associated herpesvirus,  a  major  oncogenic  virus  in  endothelial  cells  [174,  175].  Eph‐
rinB2 and EphrinB3, other family members,  have also been identified as entry receptors
for the Hendra virus and Nipah virus [176-178]. These data suggest that interfering with
Ephs  and Ephrins  could  be  an  interesting  strategy in  gene  therapy applications  by  im‐
proving the transduction of viral vectors.
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5. Concluding remarks & perspectives
Over the years, it has become clear that various systems of cell-cell communication play critical
roles not only in the normal development, architecture, remodeling and function of various
tissues and organs, but in the onset of diseases as well. Cells are social entities and need to
interact with each other in a way that ensures a favorable response to input from their
immediate micro-environment (growth, survival, cytotoxicity) and a flexible adaptation to
various roles and stress conditions. They also need to communicate during their death and
demise. These communication processes are subject to various regulatory mechanisms which,
when going awry, could result in various pathologies. One such instance where cell-cell
communication has a particularly dramatic role is cancer progression, metastasis and response
to therapeutic interventions. This reliance of cancer cells on cell-cell communication provides
a therapeutic opportunity that will be fully exploited only if the mechanisms of its normal and
aberrant functions are elucidated. This is for instance obvious when attempting to restore GJIC
to render cancer cells sensitive to enzyme/prodrug therapies.
Also, cancer cells share their microenvironment with many other cell types who are not just
neutral bystanders. In particular, invasive cancer cells have very unstable intercellular
contacts, as they keep migrating, constantly adhering to and detaching from cells on their way
and thus changing the nature of their cell-cell communications. This might be a challenging
fact when thinking of gene therapy strategies, and in fact any other type of therapy. Thus
understanding these dynamics of change during the course of tumor progression is of utmost
importance.
As progress continues in developing strategies for a more efficient and selective viral delivery
of gene therapeutics, the role of different junctions in the resistance of cancer epithelial cells
to viral infections, needs to be balanced by the advantageous use of these proteins to render
this approach more cancer-specific. In this respect, the enzyme/prodrug strategies need to be
reconsidered in the light of the new findings that involve both gap junctions and other types
of intercellular communications in the bystander effect. Examining the links between the
different types of cell-cell communication will be critical for future applications.
Finally, the impact of protein-protein interactions which are not necessarily engaged in cell
junctions but are involved in direct cell-cell interactions, and the therapeutic opportunities
they provide, will constitute a way for the future.
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